Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuliana Alimena

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
Cancer Letters|June 12, 2012
Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challengesMassimo Breccia, Giuliana Alimena
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 3, 2011
Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patientsMassimo Breccia, Giuliana Alimena
Leukemia Research|September 29, 2009
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemiaMassimo Breccia, Giuliana Alimena
Leukemia Research|March 25, 2009
The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolismMassimo Breccia, Giuliana Alimena
Mediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIsMassimo Breccia, Giuliana Alimena
Oncotargets and Therapy|December 4, 2010
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinibMassimo Breccia, Giuliana Alimena
Critical Reviews in Oncology/Hematology|August 6, 2010
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib eraMassimo Breccia, Giuliana Alimena
Cancer Letters|February 11, 2014
Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemiaMassimo Breccia, Giuliana Alimena
Drugs & Aging|April 26, 2013
Management options for refractory chronic myeloid leukemia: considerations for the elderlyMassimo Breccia, Giuliana Alimena
Cardiovascular & Hematological Disorders Drug Targets|March 12, 2009
Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problemMassimo Breccia, Giuliana Alimena
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Cancer Letters|June 12, 2012
Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challengesMassimo Breccia, Giuliana Alimena
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 3, 2011
Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patientsMassimo Breccia, Giuliana Alimena
Leukemia Research|September 29, 2009
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemiaMassimo Breccia, Giuliana Alimena
Leukemia Research|March 25, 2009
The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolismMassimo Breccia, Giuliana Alimena
Mediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIsMassimo Breccia, Giuliana Alimena
Oncotargets and Therapy|December 4, 2010
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinibMassimo Breccia, Giuliana Alimena
Critical Reviews in Oncology/Hematology|August 6, 2010
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib eraMassimo Breccia, Giuliana Alimena
Cancer Letters|February 11, 2014
Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemiaMassimo Breccia, Giuliana Alimena
Drugs & Aging|April 26, 2013
Management options for refractory chronic myeloid leukemia: considerations for the elderlyMassimo Breccia, Giuliana Alimena
Cardiovascular & Hematological Disorders Drug Targets|March 12, 2009
Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problemMassimo Breccia, Giuliana Alimena
Pageof 14